🅇
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient.
Status
Recruiting
Phase
PHASE4
NCT ID
NCT06334575
Trial Summary
The 3TR-ICS COPD study is an international, multicentre, randomized, parallel, controlled study that will recruit clinically stable former smokers COPD patients (with no exacerbations in the previous 8 weeks) on treatment with dual long-acting bronchodilators (LABA+LAMA), minimum 8 weeks of usage, not receiving ICS (either naïve or > 3 months since last usage). The overall objective of this clinical trial is to identify the molecular signatures associated with the molecular response to ICS treatment in patients with COPD stratified by the levels of circulating eosinophils, and the potential influence of the pulmonary microbiome
Sponsor: Maria Joyera Rodríguez
Participants: ALL
Start: 2025-02-12
Completion: 2027-12
Min Age: 40 Years
Eligibility Criteria
Inclusion Criteria: * Male and female patients ≥40 years of age. * ≥ 10 pack-years smoking. * Former smokers (≥6 months). * post-bronchodilator FEV1/FVC
Data from ClinicalTrials.gov. Always verify on the primary source before clinical use.
More in Respiratory / COPD / Asthma
NICE
Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management (NICE NG115)
25 Mar 2026
NICE
Asthma: Diagnosis, Monitoring and Chronic Asthma Management (NICE NG80/BTS)
25 Mar 2026
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III…
25 Mar 2026